Form 4 for YARW Yarrow Bioscience, Inc.
Accepted 2021-12-02 00:00:00 ET · period of report 2021-11-30 · accession 0001209191-21-067649 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-02 | 2021-11-30 | YARW | Zeronda Tyler | Interim CFO | A - Grant | $0.88 | +4,187 | 87.5K | +5% | +$3,685 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-30 | A | A | 4,187 | $0.88 | 87,535 | D | — | — | (F1) These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2021 and ending on November 30, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2021 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year. |